Abstract: Objective To investigate the clinical efficacy of lived combined clostridium butyricum and
bifidobacterium capsules combined with polyene phosphatidyl choline in treatment of patients with non-
alcoholic steatohepatitis (NASH). Methods Total of 84 cases with NASH in Qingdao Municipal Hospital
from January 2014 to December 2015 were selected and randomly divided into treatment group and control
group, 42cases in each group. Patients in treatment group were given lived combined clostridium butyricum
and bifidobacterium capsules in combination with polyene phosphatidyl choline orally, and patients in control
group were given polyene phosphatidyl choline only. The treatment course was 24 weeks. The liver founction
indexes (ALT, AST and GGT), serum lipid (TG, TC), serum endotoxin and Fibroscan-CAP were compared
before and after treatment. Results After treatment, the level of ALT, AST, GGT, TG, TC, serum endotoxin
and Fibroscan-CAP in both groups improved significantly (P ＜ 0.001). The decline level of ALT, AST, GGT,
TG, TC, serum endotoxin and Fibroscan-CAP in treated group were better than those in control group, the
difference was statistically significant (t = -4.600, -4.039, -2.655, -4.500, -4.151, -4.886, -2.723; P ＜ 0.05).
Conclusions Lived combined clostridium butyricum and bifidobacterium capsules, which can decrease
the level of serum lipid, relieve fatty deposition and injury of liver by regulating intestinal microflora and
attenuating intestinal endotoxemia, is an effective assistant treatment of NASH.